Inflammatory Bowel Disease – IBD

Inflammatory Bowel Disease (IBD) is a common condition that affects many people in the UK with an estimated one in every 250 people affected. The condition is often caused by Crohn’s disease (CD) and ulcerative colitis, which are long-term chronic diseases causing unpleasant and recurrent symptoms that place strain on health services. 

The IBD cohort was setup to create a bioresource of well-annotated samples linked to defined phenotypes / genotypes. The biobank has made great progress and has already provided new insights into the changes in immune cells and the mechanisms of onset of the disease.

Resource Details

  • DNA samples from patients with CD, ulcerative colitis, and IBD-unclassified
  • Serum samples
  • PBMC 
  • Fresh tissue
  • Linked clinical and pathology data


The cohort protocol forms basis of multiple collaborations with leading Pharma industry partners, including basic science studies of microbiome in IBD, biomarkers for IBD, role of IL-10 in IBD, phase II experimental medicine study based in Oxford, and continuing clinical development of Biotech-derived first-in-class chemokine receptor antagonist. For more information contact Dr. Carolina Arancibia. The Chief Investigator is Dr. Satish Keshav.